Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AGCO Corporation (AGCO) vs Heron Therapeutics Inc (HRTX) Price & Performance

AGCO CorporationTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

AGCO Corporation vs Heron Therapeutics Inc — how do they compare? AGCO Corporation trades at $101.37 (market cap $7.10B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: AGCO Corporation is far larger — about 115.5× Heron Therapeutics Inc's market cap, and AGCO Corporation pays a 1.18% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

AGCOHRTX
Market Cap
$7.10B$61.47M
Sector
IndustrialsHealth
52-Week High
$140.49$1.49
52-Week Low
$100.14$0.32
Enterprise Value
$9.37B$168.21M
Dividend Yield
1.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AGCO Corporation

AGCO trades at $101.55, up 0.67% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed estimates, leading to an 11% share drop and multiple legal investigations. The company maintains a solid balance sheet with $612M cash and a 5.15% net income margin, but faces headwinds from lowered 2026 guidance and weak agricultural demand.

The outlook is cautious; while valuation ratios like P/E of 14.03 appear attractive and analysts set a $124.63 consensus target, risks from earnings volatility, legal scrutiny, and industry softness outweigh near-term opportunities. Investors should weigh the dividend yield against potential further downside from ongoing investigations and macroeconomic pressures.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.

Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AGCO Corporation

Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.

Read more on AGCO

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX